Theratechnologies ( (TSE:TH) ) has provided an update.
Theratechnologies has received FDA approval for EGRIFTA WR™, a new formulation of tesamorelin for injection, designed to treat excess visceral abdominal fat in adults with HIV and lipodystrophy. This improved version offers a more convenient dosing schedule, requiring weekly reconstitution instead of daily, and is set to replace the current EGRIFTA SV®. The new formulation is expected to enhance patient experience and simplify administration, potentially improving management of comorbidities like lipodystrophy among HIV patients.
More about Theratechnologies
Theratechnologies Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies. The company is known for its products targeting specific unmet medical needs, particularly in the field of HIV-related conditions.
YTD Price Performance: -14.67%
Average Trading Volume: 116,230
Technical Sentiment Signal: Buy
Current Market Cap: $73.23M
For an in-depth examination of TH stock, go to TipRanks’ Stock Analysis page.